Table 3.
Clinical features and patterns of methotrexate (MTX) use at etanercept (ETN) initiationa (ETN Initiator Cohort, n = 465)
| Characteristic | Combination therapyb | Step-up therapyc | ETN proximate switchersd | ETN remote switcherse | MTX add-onf | ETN only | p-valueg |
|---|---|---|---|---|---|---|---|
| Activeh enthesitis (n = 67), n (%) | 13 (19.4) | 15 (22.4) | 11 (16.4) | 6 (9.0) | 3 (4.5) | 19 (28.4) | 0.073 |
| Active sacroiliitis (n = 33), n (%) | 4 (12.1) | 8 (24.2) | 5 (15.2) | 2 (6.1) | 1 (3.0) | 13 (39.4) | |
| Active joint count, n | 91 | 187 | 56 | 31 | 14 | 78 | |
| Median (IQR) | 11.0 (4.0, 20.0) | 4.0 (2.0, 8.0) | 2.0 (1.0, 8.0) | 3.0 (1.0, 8.0) | 9.0 (4.0, 17.0) | 4.0 (1.0, 7.0) | <.001 |
| CHAQi, n | 83 | 146 | 42 | 22 | 11 | 65 | |
| Median (IQR) | 0.9 (0.4, 1.5) | 0.4 (0.1, 1.0) | 0.6 (0.1, 1.1) | 0.3 (0.0, 0.6) | 0.8 (0.4, 2.0) | 0.6 (0.0, 1.0) | <.001 |
| cJADAS 10j, n | 81 | 145 | 47 | 23 | 8 | 61 | |
| Median (IQR) | 19.0 (13.0, 22.0) | 11.0 (7.5, 16.0) | 10.5 (6.0, 16.0) | 11.0 (6.0, 16.0) | 18.8 (14.0, 23.0) | 11.5 (8.0, 17.0) | <.001 |
| Physician Global, n | 89 | 175 | 50 | 29 | 13 | 74 | |
| Median (IQR) | 5.0 (3.5, 7.0) | 3.0 (2.0, 5.0) | 3.0 (2.0, 4.0) | 3.0 (2.0, 4.0) | 6.0 (3.0, 7.0) | 4.0 (2.0, 6.0) | <.001 |
| Patient Global, n | 82 | 151 | 49 | 24 | 9 | 69 | |
| Median (IQR) | 5.0 (2.0, 6.0) | 3.0 (1.0, 5.0) | 4.0 (1.0, 5.0) | 3.0 (1.5, 5.0) | 6.0 (4.0, 6.0) | 4.0 (2.0, 6.0) | 0.022 |
| Paink, n | 66 | 123 | 34 | 19 | 8 | 56 | |
| Median (IQR) | 5.0 (2.0, 7.0) | 3.0 (2.0, 6.0) | 4.5 (2.0, 7.0) | 4.0 (1.0, 7.0) | 6.5 (5.0, 9.0) | 4.5 (2.0, 6.0) | 0.014 |
a Study visit must have been within 30 days prior to or after date of etanercept (ETN) initiation; b combination therapy = methotrexate (MTX) started concurrently with ETN; c step-up therapy = MTX started > 1 month prior to ETN and continued > 1 month after ETN; d proximate switchers = MTX started> 1 month prior to ETN and discontinued within 1 month prior to or after ETN; e ETN remote switchers = MTX discontinued > 1 month prior to start of ETN; f MTX add-on = MTX started > 1 month after starting ETN; gp-values were calculated across all JIA categories using Pearson’s Chi Square or Fisher’s exact tests for categorical variables, and Wilcoxon rank sum, Kruskal-Wallis, or analysis of variance (ANOVA) for continuous variables depending on normality and the number of groups being compared; hactive clinically active, iCHAQ Childhood Health Assessment Questionnaire, jcJADAS 10 clinical Juvenile Arthritis Disease Activity Score (10 joints); k Pain measured on a Likert scale from 0 (no pain) to 10 (worst pain)